Biotechnology Breakthrough for Asthma

FDA approves Xolair, the first humanized antibody to target IgE, responsible for asthma with an allergic component

24-Jun-2003 - Genentech, Inc.Novartis Pharmaceuticals Corporation and Tanox, Inc. announced that the novel IgE-blocker Xolair® (Omalizumab) for subcutaneous use has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe persistent asthma in adults and adolescents. ...

Amarillo Bioscience, Inc. enters supply agreements in Taiwan, China and Pakistan for Maxisal(TM)

23-Jun-2003 - Amarillo Biosciences, Inc. announces supply agreements with STC International for the territories of China and Taiwan and with Majsons Corporation for the territory of Pakistan. Maxisal(TM), a patented dietary supplement, is the trade name for pharmaceutical grade anhydrous crystalline maltose, ...

Cooperation between BioVisioN and Roche Diagnostics

Roche Diagnostics is validating new marker candidates for diagnosis of Alzheimer Disease

28-May-2003 - Since entering into a cooperation project with Roche Diagnostics GmbH of Mannheim in 1999, Hanover-based biotechnology firm BioVisioN has identified a number of proteins that may enable early diagnosis of Alzheimer's Disease and distinguish it from other forms of dementia. The cooperation between ...

German biotechnology firms can win space and services in a U.S. business incubator

27-May-2003 - The Fairfax County Economic Development Authority (FCEDA) and two German biotechnology groups, Munich-based BioM AG and BioTOP Berlin Brandenburg, are holding a competition to help German biotech companies expand into the U.S. market around Washington, D.C. The deadline for entries is Saturday, ...

Monsanto executive says rigorous process for research investments balances near- and longer-term priorities

09-May-2003 - A rigorous process aligning Monsanto's research-and-development (R&D) portfolio with corporate strategy allows the company to balance its near- and longer-term priorities, according to Robert T. Fraley, Ph.D., chief technology officer. "The cross-functional process we've employed for more than a ...

Celltech announces appointment of new chief executive officer

17-Apr-2003 - Celltech Group plc today announced the appointment of Dr. Goran Ando (54) as CEO, with immediate effect. Dr. Ando served as President of R&D at Pharmacia Corporation until its acquisition by Pfizer, which completed on 15 April 2003. Dr. Ando's extensive business role as an Executive Vice ...

Dupont and Monsanto sign licensing agreement for rootworm-protected corn technology

16-Apr-2003 - DuPont and its subsidiary, Pioneer Hi-Bred International Inc., and Monsanto Company announced today they have agreed to a worldwide licensing agreement to Monsanto's recently approved YieldGard Rootworm insect-protected corn technology. "This licensing agreement allows us to provide our ...

BIOGEN BREAKS GROUND ON LARGE-SCALE MANUFACTURING FACILITY IN DENMARK

First Major International Manufacturing Facility will be one of the Largest in the World

04-Apr-2003 - Cambridge, MA and Hillerød, Denmark - Biogen, Inc. joined by local and national officials and business leaders, today broke ground on a large-scale manufacturing facility in the Municipality of Hillerød, Denmark. Biogen also celebrated its 25th anniversary. The large-scale manufacturing facility ...

Genzyme Biosurgery, Excigen to Collaborate in Developing Gene Therapy for Cardiac Arrhythmias

01-Apr-2003 - Genzyme Biosurgery, a division of Genzyme Corp., announced today that it has entered into a collaboration with Excigen, Inc., a recently created biotechnology company in Baltimore, Maryland focused on developing gene therapies for treating cardiac arrhythmias. Genzyme Biosurgery, which has an ...

Dramatic fall in EU genetically modified organism research, says report

25-Mar-2003 - According to a new Joint Research (JRC) report, plant biotechnology research has dropped in the EU by 76% since 1998. The report attributes this fall mainly to the Environment Ministers' decision in 1999 to block any new approvals of genetically modified (GM) products in Europe. "The findings ...